Primary biliary cirrhosis is a chronic autoimmune liver disease in which the body’s immune system slowly destroys the small bile ducts inside the liver. As these ducts are damaged, bile builds up in the liver tissue, causing inflammation and progressive scarring. The condition was officially renamed “primary biliary cholangitis” (PBC) in 2015, but many people still search for it by its original name.
Why the Name Changed
The word “cirrhosis” implies end-stage liver scarring, but most people diagnosed with this condition never reach that point, especially with modern treatment. Patient advocacy groups in the UK and Germany pushed for the change, arguing that the old name was medically inaccurate and carried a stigma of alcohol abuse and poor prognosis. Major liver disease organizations in Europe and the United States approved the switch between 2014 and 2015, settling on “primary biliary cholangitis,” which simply means inflammation of the bile ducts. You may still see either name in older lab reports or medical records.
What Happens Inside the Liver
Your liver produces bile, a digestive fluid that flows through a network of tiny tubes called bile ducts before reaching the intestine. In PBC, the immune system mistakes the cells lining these small ducts as foreign and attacks them. The attack is led primarily by two types of immune cells. One type directly kills bile duct cells, while the other produces inflammatory signals that amplify the assault and trigger antibody production. At the same time, the body’s regulatory immune cells, which normally keep autoimmune reactions in check, are reduced in both the liver and the bloodstream.
Once bile ducts are damaged, bile can’t drain properly. It pools in the liver, irritating surrounding tissue and gradually causing fibrosis (scar tissue). Over years or decades, if untreated, this scarring can progress to cirrhosis. But with early diagnosis and treatment, many people never develop significant scarring at all.
Common Symptoms
Fatigue is the single most common symptom, reported in up to 80% of patients, with roughly 40% describing it as severe. This isn’t ordinary tiredness. Many people with PBC describe a deep, persistent exhaustion that doesn’t improve with rest and can significantly interfere with daily life and social activity.
Itching (pruritus) is the second most common symptom, affecting between 20% and 70% of patients. It tends to be worse at night and can range from mildly annoying to debilitating. The itching is caused by bile salts and other substances that accumulate in the skin when bile flow is impaired.
Many people, however, have no symptoms at all when they’re first diagnosed. The condition is often discovered incidentally through routine blood work showing elevated liver enzymes, particularly alkaline phosphatase (ALP). Dry eyes and dry mouth are also common, since PBC frequently overlaps with Sjögren’s syndrome, another autoimmune condition.
How It’s Diagnosed
Diagnosis is usually straightforward and rarely requires a liver biopsy. A doctor looks for two of three criteria: elevated alkaline phosphatase on a blood test, a positive result for antimitochondrial antibodies (AMA), or biopsy findings showing characteristic bile duct damage. AMA is present in 90% to 95% of people with PBC and is highly specific to the disease, making it a reliable marker.
A liver biopsy is considered when blood tests are inconclusive or when doctors suspect an overlap with autoimmune hepatitis, a related but distinct condition. It can also help determine how much scarring has already occurred, which influences treatment decisions. But for the majority of patients, two blood tests are enough to confirm the diagnosis.
Treatment With Bile Acid Therapy
The first-line treatment is ursodeoxycholic acid (UDCA), a medication taken daily that helps bile flow more freely through the liver and reduces the toxic effects of bile buildup. It’s dosed by body weight. After one year of treatment, doctors check whether alkaline phosphatase levels have dropped sufficiently, which is the primary measure of whether the drug is working.
For people who respond well to UDCA, the long-term outlook is very good. In one large analysis, survival rates without serious liver complications were 96% at five years and 91% at ten years among responders. That’s close to the life expectancy of the general population.
Around 40% of patients, however, don’t achieve an adequate biochemical response to UDCA alone. For these individuals, a second medication can be added. Current evidence suggests that fibrate-based medications may produce a greater reduction in alkaline phosphatase than other second-line options, though the best choice depends on individual factors. Research into additional therapies is active, and options have expanded considerably in recent years.
Bone Health and PBC
Osteoporosis is a common complication, affecting roughly 30% of people with PBC overall and up to 44% of those with advanced liver disease. The primary driver is reduced bone formation: elevated bilirubin and bile salts appear to impair the cells responsible for building new bone. Postmenopausal women with PBC face a compounded risk, since hormonal changes also accelerate bone loss.
Because of this, bone density screening is an important part of ongoing care. The severity of bone loss tends to track with the severity and duration of the underlying liver disease, so effective treatment of PBC itself is one of the best ways to protect your bones. Standard osteoporosis therapies, including calcium and vitamin D supplementation, are commonly recommended. Osteomalacia, a different bone-softening condition once thought to be common in PBC, turns out to be quite rare.
Who Gets PBC
PBC overwhelmingly affects women, who account for roughly 90% of cases. It’s most commonly diagnosed between the ages of 40 and 60, though it can appear earlier. The exact cause remains unknown, but a combination of genetic susceptibility and environmental triggers is the leading theory. Having a first-degree relative with PBC increases your risk significantly. Urinary tract infections, smoking, and certain environmental chemicals have all been studied as possible triggers, though none has been definitively proven.
The disease occurs worldwide but is diagnosed most frequently in Northern Europe and North America, which may reflect both genetic patterns and differences in screening practices.
Living With PBC
PBC is a lifelong condition, but for most people diagnosed early and treated consistently, it progresses slowly or not at all. Regular blood work, typically every three to six months, tracks how well your liver is responding to treatment. Beyond medication, managing symptoms like itching and fatigue often requires its own set of strategies, since these symptoms don’t always improve with bile acid therapy alone.
For the small percentage of patients who progress to advanced cirrhosis despite treatment, liver transplantation is an option with excellent outcomes. PBC can recur in the transplanted liver, but recurrence is usually mild and rarely leads to graft failure. The vast majority of people with PBC, however, will never need a transplant.